Search 

Crystec Pharma is focused on applying supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Applications of our mSAS® (modified Supercritical Anti-Solvent) technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.

Our solutions include the following:

• Crystal and particle engineering

• Stabilisation of therapeutic agents derived from biotechnology

• Polymorph screening

• Improved performance of poorly soluble drugs

• Improved bioavailabilty of small molecules

• Alternative routes of delivery such as inhaled therapy

• Taste masking

• Crystallisation seeds

• Residual solvent elimination

Mereo BioPharma is a UK-based international biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT) has completed a Phase 1a dose-escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges. 

Therakind, a private European pharmaceutical company, is focused on creating and developing safe, effective, authorised paediatric and speciality niche medicines. Our primary objective is to increase the availability of authorised paediatric and niche medicines and to ensure that the medication used today is both safe and effective.

Therakind's team has extensive experience in the paediatric pharmaceutical sector, we have the expertise to design clinical programmes and regulatory strategy to advance medicines from concept through to regulatory approval.

Therakind was pivotal in the process of bringing Buccolam®, a treatment for prolonged acute convulsive seizures, to the EU market. This product has been sold to Viropharma Inc (now Shire Pharmaceuticals) and is marketed across Europe.

Therakind is a private European pharmaceutical company established in 2006.